All Data
Development, Manufacturing & Marketing of Pharmaceuticals for Central Nervous System Pathologies.
Lead Product(s): Cannabis products
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Panaxia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 22, 2020
Details:
The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): Wnt Activating Antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Surrozen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 29, 2020
Details:
Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
The completion of the CIDS enrollment stage follows the U.S. Food and Drug Administration (FDA)’s recent agreement to allow the NexoBrid expanded access (NEXT) protocol to be expanded to include pediatric as well as adult burn patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-04457845
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PF-04457845
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $410.0 million Upfront Cash: $35.0 million
Deal Type: Acquisition October 26, 2020
Details:
Under the terms of the agreement, SpringWorks has assigned and exclusively licensed all assets relating to its FAAH inhibitor program to Jazz, including SpringWorks' proprietary FAAH inhibitor PF-04457845 and its license agreement with Pfizer, Inc.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Ghrelin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OXE103
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
The Randomized, placebo controlled phase 2 study aims to reduce symptom burden with OXE103 treatment. Measures of cognition and balance will also be tracked to provide objective assessment of recovery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NTX-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Company announced activation of it first clinical site of its Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Patients with Acute Single Transected Peripheral Nerve Injuries of the Upper Extremities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BP-C2
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recce 327
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Recce 327
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Study will assess safety and efficacy of RECCE® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The FDA response provided clear feedback on the proposed plan and outlined the critical steps to test XRx-101 in patients with COVID-19 infection to treat acute kidney injury (“AKI”).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CX717
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CX717
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Studies describes the ability of CX717, one of the Company’s lead ampakines, to improve motor nerve function in an animal model of spinal cord injury. CX717 improved the electrical activity of the phrenic motor nerve when recorded below the site of the spinal injury.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
